News · 26 weeks32+67%
2026-04-262026-10-18
Mix1590d
- SEC Filings5(33%)
- Earnings4(27%)
- Analyst3(20%)
- Other2(13%)
- Insider1(7%)
Latest news
25 items- SECSEC Form PRE 14A filed by Zymeworks Inc.PRE 14A - Zymeworks Inc. (0001937653) (Filer)
- PRZymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial ResultsVANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its third quarter 2026 financial results after market close on November 9, 2026. Consistent with its current practice, Zymeworks does not plan to host a conference call or webcast for its third quarter 2026 financial results. Management looks forward to engaging with the investment community at upcoming events. Investor Conference Participation Zymeworks also announced that management will participate
- INSIDERSEC Form 4 filed by Zymeworks Inc.4 - Zymeworks Inc. (0001937653) (Issuer)
- ANALYSTTD Cowen initiated coverage on Zymeworks with a new price targetTD Cowen initiated coverage of Zymeworks with a rating of Buy and set a new price target of $34.00
- PRZymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma AcquisitionAcquisition diversifies durable cash flows and advances Zymeworks’ strategy to build a productive R&D company with a growing portfolio of revenue-generating assetsYUPELRI® expected to contribute immediately accretive revenue and cash flow to Zymeworks with base case mid-teens IRRZymeworks to retain existing commercial organization supporting YUPELRI hospital promotionThe Company expects total revenue, including collaboration revenue from YUPELRI, for 2026 to be between $278 million and $292 million and 2026 Adjusted EBITDA to be between $114 million and $128 millionConference call with Zymeworks management today at 8:30 am Eastern Time (ET) VANCOUVER, British Columbia, Sept. 28, 2026 (GLO
- SECZymeworks Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Zymeworks Inc. (0001937653) (Filer)
- PRZymeworks Completes Acquisition of Theravance BiopharmaConference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET) VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today completed the previously announced acquisition of Theravance Biopharma. With the completion of the transaction, Theravance Biopharma is now part of Zymeworks, further advancing Zymeworks’ strategy to build a diversified revenue-generating biotechnology company, combining innovative R&D with growing commercial and royalty-based cash flows. Zymeworks will
- ANALYSTWolfe Research initiated coverage on ZymeworksWolfe Research initiated coverage of Zymeworks with a rating of Outperform
- ANALYSTH.C. Wainwright reiterated coverage on Zymeworks with a new price targetH.C. Wainwright reiterated coverage of Zymeworks with a rating of Buy and set a new price target of $55.00 from $51.00 previously
- SECZymeworks Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Zymeworks Inc. (0001937653) (Filer)
- PRU.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal AdenocarcinomaZiihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, providing a new treatment option in front-line GEASecond FDA approval for zanidatamab in less than two years further validates Zymeworks’ proprietary Azymetric™ bispecific antibody platform and internal discovery engineFDA approval triggers a $250 million milestone payment from Jazz Pharmaceuticals, with Zymeworks remaining eligible for up to $1.3 billion in additional milestones plus tiered royalties of up to 20.0% on net salesThrough its Asia Pacific collaboration with BeOne, Zymeworks remains eligible for up to $144 million in addition
- PRZymeworks Announces Participation in Upcoming Investor ConferencesVANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and fireside chat on September 8 at 3:45 pm Eastern Time (ET) in Boston, MA.Citi’s Biopharma Back to School Summit: Zymeworks’ management will participate in one-on-one meetings and fireside chat on September 9 at 3:40 pm ET in New York, NY.Morgan Stanley
- SECSEC Form 10-Q filed by Zymeworks Inc.10-Q - Zymeworks Inc. (0001937653) (Filer)
- SECZymeworks Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Zymeworks Inc. (0001937653) (Filer)
- PRZymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsAugust 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million U.S. approval milestone and up to $190 million in potential additional global regulatory milestonesAcquisition of Theravance Biopharma, Inc. expected to close in 2H 2026, adding durable commercial cash flows and expanding Zymeworks' diversified revenue baseContinued advancement of R&D pipeline across wholly-owned and partnered programsRepurchased $49.4 million of common shares as of August 4, 2026 under the newly authorized 2026 share repurchase programStrong balance sheet with $322.5 million in cash, cash equivalents and marketable securities as of June 30, 2026 VANCOUVER, British Columbia,
- PRZymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2026 financial results after market close on August 6, 2026. In light of the previously announced proposed acquisition of Theravance Biopharma, Zymeworks has elected not to host a second quarter earnings conference call after release of its financial results. We look forward to providing an update following the expected closing of the proposed acquisition of Theravance Biopharma, shar
- INSIDEREVP & Chief Operating Officer Hollywood Mark was granted 939 shares, increasing direct ownership by 0.71% to 133,852 units (SEC Form 4)4 - Zymeworks Inc. (0001937653) (Issuer)
- PRA Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting DrugsIssued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) said it has integrated AI-based tools across the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, efficiency gains the company expects to push multiple new development candidates into pre-IND development in 2027.SAN FRANCISCO, July 6, 2026 /CNW/ -- American News Group News Commentary, Artificial intelligence has become a fixture in biotech marketing, but the more consequential question is where it is actually used: in the slide deck, or at the bench. GT Biopharma, Inc. (NASDAQ:GTBP), a clinical-stage immuno-oncology company, says it is applying AI to the latter, embedding AI-bas
- SECZymeworks Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Zymeworks Inc. (0001937653) (Filer)
- PRZymeworks to Acquire Theravance Biopharma, Inc.Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolioAcquisition of Theravance Biopharma at $17 per share is supported by an innovative non-recourse financing structure that enhances shareholder value by minimizing Zymeworks’ net capital at risk Transaction expected to be accretive to earnings and cash flow upon closing. YUPELRI® U.S. profit share and ex-U.S. royalties generate ~$60 million annualised cash flow at current run-rates, with continued expected growthTransaction financed primarily by $350 million non-recourse note secured solely by U.S. YUPELRI® profit s
- PRGandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug DiscoveryVancouver-based biotech companies Gandeeva Therapeutics and Zymeworks have partnered to generate cryo-EM–based structural data to augment antibody drug discovery.VANCOUVER, BC, June 18, 2026 /PRNewswire/ - Gandeeva Therapeutics, Inc., a biotech at the forefront of cryo-electron microscopy (cryo-EM)–driven drug design, and Zymeworks Inc. (NASDAQ:ZYME), a global biotechnology company, have partnered to visualize structures of antibody-antigen interfaces at high resolution.While cryo-EM is now used routinely to determine structures of antibody complexes formed with compact and well-folded antigens, mapping antibody epitope footprints on small and flexible antigens remains highly challenging. In
- PRZymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression levelConfirmed objective response rate (cORR) of 78.6% in FRα-positive (≥75% at PS2+) platinum-resistant ovarian cancer patients and 47.4% in FRα-negative patients (<75% at PS2+) across all dose levels studiedMedian duration of response was not reached at the time of data cutoff, and median progression-free survival was 7.6 months across ovarian and endometrial cancer cohortsPatient recruitment in dose optimization cohorts completed, with favorable tolerability profile and broad therapeutic window supporting continued clinical development VANCOUVER, British Columbia,
- ANALYSTTruist resumed coverage on Zymeworks with a new price targetTruist resumed coverage of Zymeworks with a rating of Buy and set a new price target of $28.00
- INSIDERSEC Form 4 filed by EVP, General Counsel Schneider Paul R4 - Zymeworks Inc. (0001937653) (Issuer)
- INSIDERNew insider Schneider Paul R claimed no ownership of stock in the company (SEC Form 3)3 - Zymeworks Inc. (0001937653) (Issuer)
ZYME FAQ
6 questionsWhat does Zymeworks Inc. do?
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic...Where does ZYME stock trade?
Zymeworks Inc. (ZYME) is listed on NYSE.What sector and industry is ZYME in?
Zymeworks Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ZYME?
Zymeworks Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy with a $3400.00 price target on 2026-09-29. Recent price targets range from $1500.00 to $3400.00.What companies are similar to ZYME?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ZYME side-by-side with any of them on Quantisnow.How can I track ZYME on Quantisnow?
Quantisnow aggregates Zymeworks Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZYME to receive live email and push alerts on every new disclosure.